Developing a self-monitoring device for COVID-19 antibody response

In partnership with the National Science Foundation, HIA has developed a remote or home-based self-monitoring system to identify anti-SARS-CoV-2 antibodies (IgG and IgM) and inflammatory biomarkers from finger-stick blood after natural viral exposure or vaccine. Specifically, this technology combines serial serology, lateral flow immunochromatographic assays, and novel app-enabled spectrophotometry to evaluate immune health during the course of infection. This approach will provide novel information and data for large-scale analysis and mitigation measures.

The broader impact and commercial potential of this project is to generate personalized data regarding immune health and exposure to SARS-CoV-2 as well as looking at vaccine efficacy of individuals. Detection of SARS-CoV-2 exposure is urgently needed to understand viral spread, conduct contact tracing, provide public health recommendations, prepare for hospitalization or critical care emergencies. The proposed system will use new technologies to measure chemicals in blood to understand how COVID-19 evolves after exposure. This approach offers improved speed, accuracy, ease of use, cost, and ability to deploy in communities where clinical resources may not be readily accessible.

For more information about Absure, please visit the link below…

Scroll to Top